

## Free NARCAN® (naloxone HCl) Nasal Spray for Schools Order form and Terms and Conditions

The College/ and or University identified below (herein, the “School”) hereby acknowledges and agrees that NARCAN® (naloxone hydrochloride) Nasal Spray 4mg (“NARCAN®”, NDC # 69547-353-02) will be made available by Adapt Pharma, Inc. (“Adapt Pharma”) and distributed through Smith Medical Partners, LLC (“SMP”) to the School free of charge under the *Free NARCAN® (naloxone HCl) Schools Program*. Receipt by the School of this free Narcan is conditioned upon the undersigned signing the following certification that the School represents and warrants to Adapt Pharma and SMP the following:

1. The undersigned is a Title IV degree-granting institutions, either colleges or universities in the country. These may be public universities, private universities, liberal arts colleges, community colleges, or for-profit colleges whose primary purpose is education for students and is licensed as an educational facility.
2. The School will only purchase, receive, dispense and/or use NARCAN® in accordance with all applicable laws, rules and regulations. In addition, the School will provide to Adapt and/or SMP the appropriate medical license of the registered medical advisor representing the School and overseeing its receipt of Narcan and its administration and dispensing. Narcan will only be dispensed and used in accordance with its FDA-approved labeling, including prescribing information and Instructions for Use.
3. The School is solely responsible for the proper and safe usage of the product, and training of any school personnel who administer NARCAN® and will indemnify Adapt Pharma and SMP against any and all claims regarding the receipt, dispensing or administration of the NARCAN® product.
4. NARCAN® received by the School will be for the School’s own use and the School shall not sell or transfer NARCAN® received pursuant to the Free NARCAN® Schools Program to any third party.
5. NARCAN® (naloxone HCl) nasal spray 4mg received under this program is not returnable or refundable.
6. The order quantity pursuant to the Free NARCAN® Schools Program is limited to **four units per School**.
7. Adapt Pharma may fulfil or refuse orders, or amend the Terms and Conditions, or discontinue the Free NARCAN® Program, at any time, at its sole discretion. The individual signing the Purchase Order and Terms and Conditions has all requisite authority to do so on behalf of the School. All of the information provided by the School is true, complete and accurate.

**I have read and certify to the foregoing terms and conditions:**

### Authorized Representative

### School

\_\_\_\_\_  
Print Name

\_\_\_\_\_  
Name of School

\_\_\_\_\_  
Signature

\_\_\_\_\_  
Address

\_\_\_\_\_  
Date

\_\_\_\_\_  
City, State, Zip Code

\_\_\_\_\_  
Prescriber License # / State

\_\_\_\_\_  
Telephone Number      Contact Person

\_\_\_\_\_  
Email

**Please scan/email the signed completed Certification Form to Adapt Pharma, Inc  
For program questions, please call Adapt Pharma @ 844-232-7811.**

**Scan/Email: [schoolsprogram@adaptpharma.com](mailto:schoolsprogram@adaptpharma.com)**

# Free NARCAN® (naloxone HCl) Nasal Spray for Schools Order form and Terms and Conditions

## NARCAN® NASAL SPRAY INDICATIONS AND IMPORTANT SAFETY INFORMATION

### INDICATIONS

NARCAN® (naloxone hydrochloride) Nasal Spray is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. NARCAN® Nasal Spray is intended for immediate administration as emergency therapy in settings where opioids may be present. NARCAN® Nasal Spray is not a substitute for emergency medical care.

### IMPORTANT SAFETY INFORMATION

NARCAN® Nasal Spray is contraindicated in patients known to be hypersensitive to naloxone hydrochloride.

Seek emergency medical assistance immediately after initial use, keeping the patient under continued surveillance.

Risk of Recurrent Respiratory and CNS Depression: Due to the duration of action of naloxone relative to the opioid, keep the patient under continued surveillance and administer repeat doses of naloxone using a new nasal spray with each dose, as necessary, while awaiting emergency medical assistance.

Risk of Limited Efficacy with Partial Agonists or Mixed Agonists/Antagonists: Reversal of respiratory depression caused by partial agonists or mixed agonists/antagonists, such as buprenorphine and pentazocine, may be incomplete. Larger or repeat doses may be required.

Precipitation of Severe Opioid Withdrawal: Use in patients who are opioid dependent may precipitate opioid withdrawal characterized by body aches, diarrhea, increased heart rate (tachycardia), fever, runny nose, sneezing, goose bumps (piloerection), sweating, yawning, nausea or vomiting, nervousness, restlessness or irritability, shivering or trembling, abdominal cramps, weakness, and increased blood pressure. In neonates, opioid withdrawal may be life-threatening if not recognized and properly treated and may be characterized by convulsions, excessive crying, and hyperactive reflexes. Monitor for the development of opioid withdrawal.

Risk of Cardiovascular (CV) Effects: Abrupt postoperative reversal of opioid depression may result in adverse CV effects. These events have primarily occurred in patients who had pre-existing CV disorders or received other drugs that may have similar adverse CV effects. Monitor these patients closely in an appropriate healthcare setting after use of naloxone hydrochloride.

The following adverse reactions were observed in a NARCAN Nasal Spray clinical study: increased blood pressure, musculoskeletal pain, headache, nasal dryness, nasal edema, nasal congestion, and nasal inflammation.

See Instructions for Use and full prescribing information in the use of this product. [Clickhere](#)

To report SUSPECTED ADVERSE REACTIONS, contact Adapt Pharma, Inc. at 1-844-4NARCAN (1-844-462-7226) or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).

[If this is being sent in hard copy, then enclose a full PI and a statement to see the full PI. If it is going out via email, then include a cite/link to the full PI page and a statement to see the full PI.]